Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.
Psychedelic Alpha’s Josh Hardman sits down with Yale psychiatrist and researcher Samuel Wilkinson to unpack what current data and clinical experience tell us about ketamine and Spravato’s use in depression, the challenges of scaling rapid-acting mental health treatments, and implications for psychedelics.
One and Done? FDA to Approve Drugs on a Single Phase 3, What It Means for Psychedelics • Freedom to Heal Act Seeks to Close Federal Right to Try Gap for Psychedelics • Compass Clarifies Q1 Readout Plans • DEA Increases Aggregate Production Quotas for Psychedelics • Sinema’s Ibogaine Experience • and more…
Psychedelic Alpha’s Josh Hardman reports from Washington, D.C., where conversations with regulators, lawmakers, and insiders suggest a turbulent but potentially transformative period ahead. Amid the noise, there remains quiet confidence that multiple psychedelic approvals could land within the next 18 months.
Psychedelic Alpha’s Josh Hardman sits down with Compass Pathways’ Chief Patient Officer, Steve Levine, at a pivotal time for the company. In this wide-ranging discussion, the pair cover these commercialisation-related topics, from the clinical infrastructure and credentialing through to comps and competition.
The Advanced Research Projects Agency for Health (ARPA-H) has carved out up to $100M for an initiative that aims to develop objective measures of mental and behavioural health, it announced today. Here, we take a closer look about ARPA-H’s first major foray into mental health, and how it could catalyse psychedelic drug development and practice.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
Archived versions of our Psychedelic News Feed.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 01, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing November 24, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing November 17, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing November 22, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing November 3, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing October 27, 2025.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
